An Open Randomized Comparison of Gatifloxacin versus Cefixime for the Treatment of Uncomplicated Enteric Fever

被引:61
作者
Pandit, Anil [1 ]
Arjyal, Amit [1 ]
Day, Jeremy N. [2 ,3 ,4 ]
Paudyal, Buddhi [1 ]
Dangol, Sabina [1 ]
Zimmerman, Mark D. [1 ]
Yadav, Bharat [1 ]
Stepniewska, Kasia [2 ]
Campbell, James I. [2 ,3 ]
Dolecek, Christiane [2 ,3 ]
Farrar, Jeremy J. [2 ,3 ]
Basnyat, Buddha [1 ,5 ]
机构
[1] Patan Hosp, Lagankhel, Lalitpur, Nepal
[2] Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam
[3] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England
[4] N Manchester Grp Hosp, Reg Infect Dis Unit, Manchester, Lancs, England
[5] Nepal Int Clin, Kathmandu, Nepal
来源
PLOS ONE | 2007年 / 2卷 / 06期
基金
英国惠康基金;
关键词
D O I
10.1371/journal.pone.0000542
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective. To assess the efficacy of gatifloxacin versus cefixime in the treatment of uncomplicated culture positive enteric fever. Design. A randomized, open-label, active control trial with two parallel arms. Setting. Emergency Room and Outpatient Clinics in Patan Hospital, Lagankhel, Lalitpur, Nepal. Participants. Patients with clinically diagnosed uncomplicated enteric fever meeting the inclusion criteria. Interventions. Patients were allocated to receive one of two drugs, Gatifloxacin or Cefixime. The dosages used were Gatifloxacin 10 mg/kg, given once daily for 7 days, or Cefixime 20 mg/kg/day given in two divided doses for 7 days. Outcome Measures. The primary outcome measure was fever clearance time. The secondary outcome measure was overall treatment failure ( acute treatment failure and relapse). Results. Randomization was carried out in 390 patients before enrollment was suspended on the advice of the independent data safety monitoring board due to significant differences in both primary and secondary outcome measures in the two arms and the attainment of a priori defined endpoints. Median (95% confidence interval) fever clearance times were 92 hours (84-114 hours) for gatifloxacin recipients and 138 hours (105-164 hours) for cefixime-treated patients ( Hazard Ratio[ 95% CI] = 2.171 [1.545-3.051], p<0.0001). 19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out of 88 patients (1%) in gatifloxacin group( Odds Ratio [ 95% CI] = 0.031 [0.004 - 0.237], p<0.001). Overall treatment failure patients ( relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be ( 95% confidence interval) 37.6 % (27.14%-50.2%) in the cefixime group and 3.5% (2.2%-11.5%) in the gatifloxacin group (HR[95% CI] = 0.084 [0.025-0.280], p<0.0001). There was one death in the cefixime group. Conclusions. Based on this study, gatifloxacin is a better treatment for uncomplicated enteric fever as compared to cefixime. Trial Registration. Current Controlled Trials ISRCTN75784880
引用
收藏
页数:9
相关论文
共 34 条
[1]  
Ansari I, 2005, TROP DOCT, V35, P57
[2]   Enteric (typhoid) fever in travelers [J].
Basnyat, B ;
Maskey, AP ;
Zimmerman, MD ;
Murdoch, DR .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (10) :1467-1472
[3]  
Basnyat B, 2004, WILD ENVIRON MED, V15, P216, DOI 10.1580/1080-6032(2004)15[216:PROTBE]2.0.CO
[4]  
2
[5]   Typhoid and paratyphoid fever [J].
Bhan, MK ;
Bahl, R ;
Bhatnagar, S .
LANCET, 2005, 366 (9487) :749-762
[6]   THERAPY OF MULTIDRUG-RESISTANT TYPHOID-FEVER WITH ORAL CEFIXIME VS INTRAVENOUS CEFTRIAXONE [J].
BHUTTA, ZA ;
KHAN, IA ;
MOLLA, AM .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (11) :990-994
[7]  
CAMMIE FL, 2005, HARRISONS PRINCIPLES, P897
[8]  
Cao X T, 1999, Pediatr Infect Dis J, V18, P245
[9]   Pharmacokinetics of gatifloxacin in infants and children [J].
Capparelli, EV ;
Reed, MD ;
Bradley, JS ;
Kearns, GL ;
Jacobs, RF ;
Damle, BD ;
Blumer, JL ;
Grasela, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1106-1112
[10]   A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever [J].
Chinh, NT ;
Parry, CM ;
Ly, NT ;
Ha, HD ;
Thong, MX ;
Diep, TS ;
Wain, J ;
White, NJ ;
Farrar, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1855-1859